Home
/
Blood Sugar & Metabolic

A1C Test: Complete Guide to Blood Sugar Testing

REVIEWED BY
William Maish, MD MBA MPH
Clinical Product Lead
Published
April 3, 2026
Last updated
June 4, 2026
Key takeaway:

The A1C test measures the percentage of hemoglobin coated with glucose over approximately 120 days, offering a three-month average of blood sugar control. Results below 5.7% reflect normal glucose metabolism, while the 5.7–6.4% range may signal prediabetes — a window where lifestyle changes can meaningfully reduce progression risk.

Read more →
Table of contents

What A1C test means

The A1C test measures glycated hemoglobin, which forms when glucose molecules attach to hemoglobin proteins in your red blood cells. Since red blood cells live about 120 days, your A1C reflects your average blood sugar over that timeframe.

Here's the elegant part: glucose naturally sticks to hemoglobin when it's floating around in your bloodstream. The more glucose present, the more hemoglobin gets coated. Your A1C percentage tells you what portion of your hemoglobin carries this glucose coating.

This makes A1C incredibly valuable for understanding metabolic patterns. A single fasting glucose reading might look normal on a good day, but A1C reveals whether you've had blood sugar spikes over the past few months. It's like the difference between checking your speed once versus reviewing your entire driving record.

The test requires no fasting or special preparation. You can eat normally beforehand because A1C measures long-term averages, not current glucose levels. This convenience makes it an ideal screening tool and monitoring marker for metabolic health.

How to interpret A1C test results

A1C results fall into clear categories that guide your health decisions:

Normal metabolism: Below 5.7% is associated with healthy glucose regulation. Your body efficiently manages blood sugar without prolonged elevations. Most adults with healthy glucose metabolism have A1C values in the low-to-mid 5% range, below the ADA prediabetes threshold of 5.7%.

Prediabetes range: 5.7-6.4% signals impaired glucose tolerance. Your body struggles to keep blood sugar stable, particularly after meals. This range represents a critical intervention window where lifestyle changes can help reduce the risk of progression to diabetes.

Diabetes diagnosis: 6.5% or higher typically confirms diabetes, though this should always be verified with repeat testing or additional glucose measures. At this level, your body can no longer maintain normal blood sugar control.

For context, each 1% increase in A1C corresponds roughly to a 28-30 mg/dL increase in average blood glucose. An A1C of 6% equals approximately 126 mg/dL average glucose, while 7% equals about 154 mg/dL.

Even modest improvements in A1C are clinically meaningful — UKPDS data show each 1% reduction in A1C is associated with about a 14% reduction in heart attack risk and a 37% reduction in microvascular complications in people with type 2 diabetes.

What can influence A1C test results

Several factors can make your A1C higher or lower than your actual glucose control suggests, creating interpretation challenges you should understand.

Red blood cell lifespan variations: Conditions that shorten red blood cell life (like certain anemias or chronic kidney disease) can artificially lower A1C because cells don't live long enough to accumulate much glucose coating. Conversely, anything that extends cell life can elevate A1C readings.

Iron deficiency and anemia: Iron deficiency can increase A1C by affecting hemoglobin structure, while severe anemia might decrease it. If you have unusual A1C results, checking iron studies and complete blood count provides important context.

Kidney and liver function: Chronic kidney disease, liver disease, and certain medications can alter how your body processes glucose or affects red blood cell metabolism. These conditions might make A1C less reliable as a glucose control indicator.

Hemoglobin variants: Some people carry genetic variants of hemoglobin that interfere with standard A1C testing. People of African, Mediterranean, and Southeast Asian ancestry more commonly carry these variants, which can cause falsely elevated or lowered results.

Recent blood loss or transfusions also affect accuracy since they change your red blood cell population and age distribution.

Related context that changes the picture

A1C tells an important story, but other biomarkers can reveal whether your glucose patterns represent early metabolic dysfunction or established insulin resistance.

Fasting glucose and insulin: These markers show your baseline metabolic state. You might have normal A1C but elevated fasting insulin, indicating early insulin resistance that A1C hasn't yet captured. Conversely, normal fasting levels with elevated A1C suggest post-meal glucose spikes.

Fructosamine: This marker reflects 2-3 weeks of glucose control, filling the gap between daily glucose readings and A1C's three-month window. It's particularly useful when A1C accuracy is questionable or you need faster feedback on interventions.

Lipid patterns: Triglycerides often rise with poor glucose control, while HDL cholesterol typically falls. The triglyceride-to-HDL ratio provides insight into insulin sensitivity that complements A1C interpretation.

Inflammatory markers: C-reactive protein (CRP) and other inflammatory indicators can reveal whether glucose elevation stems from metabolic syndrome, chronic inflammation, or other systemic issues. This context helps guide treatment approaches.

Understanding your complete metabolic profile reveals whether A1C changes represent improving insulin sensitivity, better glucose control, or changes in factors that influence the test itself.

Take control of your metabolic health

Understanding your A1C is just the beginning. The real insight comes from seeing how it connects with your complete metabolic picture - your insulin levels, inflammatory markers, and cardiovascular risk factors.

Superpower's Advanced Blood Panel includes A1C alongside insulin, fructosamine, and comprehensive metabolic markers. You'll discover not just where your blood sugar control stands, but what's driving those patterns and how to optimize your metabolic health effectively.

Order your Advanced Blood Panel today and get the complete metabolic insights you need to take control of your health.

FAQs

For people with normal results, testing every 3 years is typically sufficient. If you have prediabetes or are managing diabetes, testing every 3-6 months helps track your progress and guide treatment adjustments.

Yes, you can eat normally before an A1C test. Unlike fasting glucose tests, A1C measures your average blood sugar over 2-3 months, so current food intake doesn't affect the results.

Daily glucose readings show your blood sugar at specific moments, while A1C reveals your average blood sugar control over 2-3 months. A1C captures patterns that daily readings might miss, including nighttime glucose levels and post-meal spikes.

Yes, certain medications can influence A1C accuracy. Drugs that affect red blood cell production or survival — including some antibiotics, antivirals, and erythropoietin therapy — can shift results independently of your actual glucose control. Always discuss your medications with your care team when interpreting A1C results.

A1C can be less reliable in people with certain conditions like anemia, kidney disease, or genetic hemoglobin variants. If you have unusual results that don't match other glucose measures, additional testing like fructosamine may provide better insight.

Fructosamine reflects 2–3 weeks of glucose control rather than 2–3 months, filling the gap between daily glucose readings and A1C's longer window. It is particularly useful when A1C accuracy is questionable due to conditions affecting red blood cell lifespan, or when you need faster feedback on dietary or lifestyle interventions.

References

  1. Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & A1c-Derived Average Glucose Study Group (2008). Translating the A1C assay into estimated average glucose values. Diabetes care, 31(8), 1473-8. https://doi.org/10.2337/dc08-0545
  2. Cohen, R. M., Franco, R. S., Khera, P. K., Smith, E. P., Lindsell, C. J., Ciraolo, P. J., Palascak, M. B., & Joiner, C. H. (2008). Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood, 112(10), 4284-91. https://doi.org/10.1182/blood-2008-04-154112
  3. Bunn, H. F., Haney, D. N., Kamin, S., Gabbay, K. H., & Gallop, P. M. (1976). The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. The Journal of clinical investigation, 57(6), 1652-9. https://doi.org/10.1172/JCI108436
  4. American Diabetes Association Professional Practice Committee (2025). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes care, 48(1 Suppl 1), S27-S49. https://doi.org/10.2337/dc25-S002
  5. Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., & Diabetes Prevention Program Research Group (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine, 346(6), 393-403. https://doi.org/10.1056/NEJMoa012512
  6. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed.), 321(7258), 405-12. https://doi.org/10.1136/bmj.321.7258.405
  7. English, E., Idris, I., Smith, G., Dhatariya, K., Kilpatrick, E. S., & John, W. G. (2015). The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review. Diabetologia, 58(7), 1409-21. https://doi.org/10.1007/s00125-015-3599-3
  8. Cavagnolli, G., Pimentel, A. L., Freitas, P. A., Gross, J. L., & Camargo, J. L. (2015). Factors affecting A1C in non-diabetic individuals: Review and meta-analysis. Clinica chimica acta; international journal of clinical chemistry, 445, 107-14. https://doi.org/10.1016/j.cca.2015.03.024
  9. Intra, J., Limonta, G., Cappellini, F., Bertona, M., & Brambilla, P. (2019). Glycosylated Hemoglobin in Subjects Affected by Iron-Deficiency Anemia. Diabetes & metabolism journal, 43(4), 539-544. https://doi.org/10.4093/dmj.2018.0072
  10. Speeckaert, M., Van Biesen, W., Delanghe, J., Slingerland, R., Wiecek, A., Heaf, J., Drechsler, C., Lacatus, R., Vanholder, R., Nistor, I., & European Renal Best Practice Guideline Development Group on Diabetes in Advanced CKD (2014). Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29(12), 2167-77. https://doi.org/10.1093/ndt/gfu006
  11. Rhea, J. M., & Molinaro, R. (2014). Pathology consultation on HbA(1c) methods and interferences. American journal of clinical pathology, 141(1), 5-16. https://doi.org/10.1309/AJCPQ23GTTMLAEVL
  12. Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012). Prediabetes: a high-risk state for diabetes development. Lancet (London, England), 379(9833), 2279-90. https://doi.org/10.1016/S0140-6736(12)60283-9
  13. Lee, J. E. (2015). Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol. Annals of pediatric endocrinology & metabolism, 20(2), 74-8. https://doi.org/10.6065/apem.2015.20.2.74
  14. Selvin, E., Rawlings, A. M., Grams, M., Klein, R., Sharrett, A. R., Steffes, M., & Coresh, J. (2014). Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. The lancet. Diabetes & endocrinology, 2(4), 279-288. https://doi.org/10.1016/S2213-8587(13)70199-2
  15. Kim-Dorner, S. J., Deuster, P. A., Zeno, S. A., Remaley, A. T., & Poth, M. (2010). Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?. Metabolism: clinical and experimental, 59(2), 299-304. https://doi.org/10.1016/j.metabol.2009.07.027
  16. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E., & Ridker, P. M. (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286(3), 327-34. https://doi.org/10.1001/jama.286.3.327
  17. American Diabetes Association Professional Practice Committee (2025). 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025. Diabetes care, 48(1 Suppl 1), S128-S145. https://doi.org/10.2337/dc25-S006
  18. Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010). Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. The New England journal of medicine, 362(9), 800-11. https://doi.org/10.1056/NEJMoa0908359

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey